Trial Information - Phase I

A Phase 1 Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of STRO-002, an anti-Folate Receptor alpha (FolRá) Antibody Drug Conjugate (ADC), in Patients with Advanced Epithelial Ovarian Cancer (including Fallopian Tube or Primary Peritoneal Cancers) and Endometrial Cancers

Protocol ID: STRO-002-GM1

Sponsor: Chiltern International/ Sutro Biopharma

Status: STUDY ON HOLD

Contact us regarding Clinical Trials at MOHRSCH@usoncology.com
or call us at 877-664-7724